Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. CALTX
CALTX logo

CALTX Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--

Events Timeline

No data

No data

News

Newsfilter
7.2
2024-07-26Newsfilter
Calliditas partner STADA receives European Commission decision for full approval of Kinpeygo® for the treatment of IgA Nephropathy
  • Approval of Kinpeygo: The European Commission has granted full marketing authorization for Kinpeygo, a treatment for adults with primary immunoglobulin A nephropathy (IgAN), expanding its label to include patients with lower levels of proteinuria.

  • Significance and Financial Impact: This approval marks the first fully approved medication for IgAN in Europe, confirming its orphan drug status and triggering a €10 million milestone payment to Calliditas Therapeutics.

PRnewswire
-.-
2024-05-23PRnewswire
Calliditas Q1 report, January - March 2024
PRnewswire
-.-
2024-05-23PRnewswire
Calliditas Q1 report, January - March 2024
Newsfilter
1.6
2024-07-04Newsfilter
Launch of Phase 3 clinical trial with Nefecon in Japan
  • Calliditas Therapeutics Announcement: Calliditas Therapeutics AB partners with Viatris Pharmaceutical Japan G.K. to conduct a phase III clinical trial in Japan for IgA nephropathy.
  • Clinical Trial Details: The trial, named VR-205 in Japan, aims to study Japanese patients with IgA nephropathy, a retractable disease in Japan with limited treatment options.
  • Bridging Study: The trial is a bridging study requiring Japanese patients to participate in a design similar to the global NefIgArd trial.
  • License Agreement: Calliditas Therapeutics announces a license agreement with Viatris to register and commercialize specialty therapy for IgA nephropathy in Japan.
  • Contact Information: For more information, individuals can contact Åsa Hillsten, Head of IR & Sustainability at Calliditas, via phone at +46 76 403 35 43 or email at [email protected]
-.-
2024-05-16newsfilter
In-Person & Virtual R&D Day: The Anti-Fibrotic Effects of Setanaxib and TARPEYO's Mode of Action
-.-
2024-04-08newsfilter
Calliditas Therapeutics to Present Nefecon Data at the ISN World Congress of Nephrology April 13 - 16 in Buenos Aires
Wall Street analysts forecast CALTX stock price to rise
0 Analyst Rating
Wall Street analysts forecast CALTX stock price to rise
0 Buy
0 Hold
0 Sell
Current: 0.000
sliders
Low
Averages
High
Current: 0.000
sliders
Low
Averages
High
No data

No data

Valuation Metrics

The current forward P/E ratio for (CALTX) is --, compared to its 5-year average forward P/E of --. For a more detailed relative valuation and DCF analysis to assess 's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
Current PE
NaN
Overvalued PE
Undervalued PE

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
Current EV/EBITDA
NaN
Overvalued EV/EBITDA
Undervalued EV/EBITDA

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
Current PS
NaN
Overvalued PS
Undervalued PS

Financials

AI Analysis
Annual
Quarterly

Whales Holding CALTX

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is (CALTX) stock price today?

The current price of CALTX is 0 USD — it has increased 0

What is (CALTX)'s business?

What is the price predicton of CALTX Stock?

Wall Street analysts forecast CALTX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CALTX is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is (CALTX)'s revenue for the last quarter?

revenue for the last quarter amounts to NaN USD, decreased

What is (CALTX)'s earnings per share (EPS) for the last quarter?

. EPS for the last quarter amounts to USD, decreased

How many employees does (CALTX). have?

(CALTX) has 0 emplpoyees as of April 04 2026.

What is (CALTX) market cap?

Today CALTX has the market capitalization of 0.00 USD.